Atrial Fibrillation Outcome in Patients with Metabolic Syndrome.

IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Francisco Somoza-Cano MD, Brittany Smith BS, Michael Fatuyi MD, Henry Egbuchiem MD, Nkemputaife Onyechi MD, Joseph Amoah MD
{"title":"Atrial Fibrillation Outcome in Patients with Metabolic Syndrome.","authors":"Francisco Somoza-Cano MD,&nbsp;Brittany Smith BS,&nbsp;Michael Fatuyi MD,&nbsp;Henry Egbuchiem MD,&nbsp;Nkemputaife Onyechi MD,&nbsp;Joseph Amoah MD","doi":"10.1016/j.jacl.2024.04.092","DOIUrl":null,"url":null,"abstract":"<div><h3>Background/Synopsis</h3><p>Overweight, in particular, is continuously increasing in the United States of America. In this respect, metabolic syndrome is a strong risk factor for atrial fibrillation.</p></div><div><h3>Objective/Purpose</h3><p>Our study sought to estimate the clinical outcome of patients admitted for atrial fibrillation with a history of metabolic syndrome.</p></div><div><h3>Methods</h3><p>Using the National Inpatients Sample Database of 2020, patients admitted with a principal diagnosis of atrial fibrillation with or without metabolic syndrome as a secondary diagnosis were identified. The primary outcome was inpatient mortality with secondary outcomes being the restoration of cardiac rhythm, acute kidney injury (AKI), ablation, post procedure complications, cardiogenic shock, length of hospital stay and charges.</p></div><div><h3>Results</h3><p>352,160 patients were admitted for atrial fibrillation. Of those, 0.18% had a history of metabolic syndrome. Patient with metabolic syndrome were younger (65 years, 95% C1 63 – 68 VS 71, 95% CI 71 – 71). There was no difference in in-hospital mortality (p=0.1287), ablation (p=0.6724), post procedure complication (p=0.5062), cardiogenic shock (p=0.3777) and acute kidney injury (p=0.9427). We noticed that patient with metabolic syndrome had increased restoration of cardiac rhythm when compared to the general population (p=0.0027). Patient with metabolic syndrome also had increased length of hospital stay (4 days, 95% CI 3.3 – 4.8 VS 3.3, 95% CI 3.3 – 3.4) and hospital charges ($61,006.79, 95% CI 42,662.56 - $79351.02 VS $55394.37 95% CI $ 53470.79 - $57317.95).</p></div><div><h3>Conclusions</h3><p>The study shows there is no statistically significant difference in inpatient mortality among patients with metabolic syndrome when compared to the general population admitted for atrial fibrillation. Patient with metabolic syndrome had increased restoration of cardiac rhythm, length of hospital stays and charges.</p></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"18 4","pages":"Page e556"},"PeriodicalIF":3.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1933287424001399","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Synopsis

Overweight, in particular, is continuously increasing in the United States of America. In this respect, metabolic syndrome is a strong risk factor for atrial fibrillation.

Objective/Purpose

Our study sought to estimate the clinical outcome of patients admitted for atrial fibrillation with a history of metabolic syndrome.

Methods

Using the National Inpatients Sample Database of 2020, patients admitted with a principal diagnosis of atrial fibrillation with or without metabolic syndrome as a secondary diagnosis were identified. The primary outcome was inpatient mortality with secondary outcomes being the restoration of cardiac rhythm, acute kidney injury (AKI), ablation, post procedure complications, cardiogenic shock, length of hospital stay and charges.

Results

352,160 patients were admitted for atrial fibrillation. Of those, 0.18% had a history of metabolic syndrome. Patient with metabolic syndrome were younger (65 years, 95% C1 63 – 68 VS 71, 95% CI 71 – 71). There was no difference in in-hospital mortality (p=0.1287), ablation (p=0.6724), post procedure complication (p=0.5062), cardiogenic shock (p=0.3777) and acute kidney injury (p=0.9427). We noticed that patient with metabolic syndrome had increased restoration of cardiac rhythm when compared to the general population (p=0.0027). Patient with metabolic syndrome also had increased length of hospital stay (4 days, 95% CI 3.3 – 4.8 VS 3.3, 95% CI 3.3 – 3.4) and hospital charges ($61,006.79, 95% CI 42,662.56 - $79351.02 VS $55394.37 95% CI $ 53470.79 - $57317.95).

Conclusions

The study shows there is no statistically significant difference in inpatient mortality among patients with metabolic syndrome when compared to the general population admitted for atrial fibrillation. Patient with metabolic syndrome had increased restoration of cardiac rhythm, length of hospital stays and charges.

代谢综合征患者的心房颤动预后
背景/简介在美国,超重现象尤其在持续增加。在这方面,代谢综合征是心房颤动的一个强有力的危险因素。方法利用 2020 年全国住院病人抽样数据库,对主要诊断为心房颤动并伴有或不伴有代谢综合征作为次要诊断的住院病人进行鉴定。主要结果是住院患者死亡率,次要结果是心律恢复、急性肾损伤(AKI)、消融、术后并发症、心源性休克、住院时间和费用。其中,0.18%的患者有代谢综合征病史。患有代谢综合征的患者更年轻(65 岁,95% C1 63 - 68 VS 71 岁,95% CI 71 - 71)。在院内死亡率(P=0.1287)、消融术(P=0.6724)、术后并发症(P=0.5062)、心源性休克(P=0.3777)和急性肾损伤(P=0.9427)方面没有差异。我们注意到,与普通人群相比,代谢综合征患者的心律恢复率较高(p=0.0027)。代谢综合征患者的住院时间(4 天,95% CI 3.3 - 4.8 VS 3.3,95% CI 3.3 - 3.4)和住院费用(61,006.79 美元,95% CI 42,662.56 - 79351.02 VS 55394.37 美元,95% CI 53470.结论该研究显示,与因心房颤动入院的普通人群相比,代谢综合征患者的住院死亡率没有统计学意义上的显著差异。代谢综合征患者的心律恢复时间、住院时间和费用均有所增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
6.80%
发文量
209
审稿时长
49 days
期刊介绍: Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信